Cholangiocarcinoma — Trials

Cholangiocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

760 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 210
Recruiting: 120
Ph III recruiting: 7
Growth YoY: +17.4%
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (106)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06050252	Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery	suspended	Phase 2	27	National Cancer Institute (NCI)NIH	1	Sep 4, 2026	clinicaltrials
NCT03779100	Lenvatinib Plus PD-1 Antibody for Unresectable ICC	suspended	Phase 2	25	Shi MingOTHER	1	Jan 28, 2019	clinicaltrials